Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma | Bone Marrow Transplantation
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial | Bone Marrow Transplantation
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis | Bone Marrow Transplantation
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma - Experimental Hematology
Algorithm for patient selection and treatment with high-dose melphalan... | Download Scientific Diagram
Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan
Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation - Biology of Blood and Marrow Transplantation
Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies - Biology of Blood and Marrow Transplantation
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma | NEJM
Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
Next-Generation Sequencing to Assess the Impact of Low Dose Melphalan on Residual Disease before High-Dose Melphalan and Stem Cell Transplant in Multiple Myeloma - ScienceDirect
High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease - Kidney International
High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later | Journal of Clinical Oncology
Studies Comparing High-Dose Melphalan and Autologous SCT with... | Download Table
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma | Bone Marrow Transplantation
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115 | Bone Marrow Transplantation
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. | Semantic Scholar
Complications of high-dose Melphalan. | Download Table
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
